AQST litigation is a known trade - only a fresh document will move it now
The Opportunity
Upstream keeps a SHORT direction on a legal-action framing, which is typically bearish because it can drag duration out of the equity story and anchor investor focus on downside tails. For small pharma, litigation overhangs can also raise financing friction at exactly the wrong time in the clinical cycle.
The Timing
Edge is decaying and the signal is already spreading. INVESTIGATE here means: keep the directional bias, but do not assume the next marginal headline is new information. A tradeable upgrade would require an identifiable complaint filing, a court schedule step, or an issuer disclosure that changes expected magnitude or timeline - something that forces analysts to update numbers, not just language.
The Evidence
The upstream record shows Tier-1 presence and a high domain count, which is the fingerprint of a crowded litigation narrative. No hydrated evidence links are present in this run, and freshness is not provided at the signal level. That makes this a lifecycle warning more than a source-led edge.